Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways

• Ngā kaituhi matua: Abdullah F. AlAsmari (Author), Nemat Ali (Author), Fawaz AlAsmari (Author), Wael A. AlAnazi (Author), Musaad A. AlShammari (Author), Naif O. Al-Harbi (Author), Ali Alhoshani (Author), Homood M. As Sobeai (Author), Mohammed AlSwayyed (Author), Mohammed M. AlAnazi (Author), Nader S. AlGhamdi (Author)
• Hōputu: Pukapuka
• I whakaputaina: Elsevier, 2020-04-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Gefitinib is an effective treatment for patients with locally advanced non-small cell lung cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide, a glucagon-like peptide 1 receptor agonist, showed potent cardioprotective effects with the mechanism is yet...